Improve identification, verification, communication and coordination.
Version 2 (unedited). The Basic Needs Analysis (BNA) is a multi-sector needs analysis approach that can be applied in both sudden onset and protracted emergencies. The methodology comprises the Guidance (this document) presenting the conceptual BNA framework and related processes, and a Toolbox, whi...ch includes tools, templates, training materials, and examples drawn from its first pilot, in Borno State(Nigeria).
The BNA is conceived to go hand in hand with the Facilitator’s Guide for the Response Options Analysis and Planning (a separate document), as it is part of a broader response planning process (see The BNA within the ). It shall be carried out with other assessments on the operational environment and would not add any value if undertaken in isolation.
more
This implementation plan sets out a series of programmatic objectives, activities and outcomes for malaria surveillance strengthening in Myanmar over the next two years. This period represents a key phase as the National Malaria Control Programme (NMCP) strives to build on recent achievements in str...engthening core surveillance operations.
more
30 April 2020
| COVID-19: Essential health services
COVID-19 e oxigênio: Os dados da China sugerem que embora a maioria das pessoas com COVID-19 tenham doença leve (40%) ou moderada (40%), cerca de 15% apresentam doença grave que requer oxigenoterapia, e 5% ficam em estado crítico e precisam de tratamento em uma unidade de terapia intensiva. Alé...m disso, a maioria dos pacientes críticos com COVID-19 precisará de ventilação mecânica.2,3 Por esses motivos, as unidades de saúde que tratam da COVID-19 devem estar equipadas com oxímetros de pulso, sistemas de oxigênio em funcionamento, incluindo interfaces de administração de oxigênio de uso único. A oxigenoterapia é recomendada para todos os pacientes graves e críticos com COVID-19, em doses baixas, variando de 1-2 L/min em crianças e começando com 5 L/min em adultos com cânula nasal, fluxos moderados para o uso em máscara de Venturi (6-10 L/min); ou fluxos mais altos (10-15 L/min) com o uso de uma máscara com bolsa reservatório. Além disso, o oxigênio pode ser administrado em fluxos mais altos e em concentrações maiores, usando uma cânula nasal de alto fluxo (CNAF)
more
Manual of Operations
First Edition 2016
Обеспечение возможностей быстрого развертывания сил и средств для оказания неотложной помощи и интенсивного лечения (6 апреля 2020 г.)
Главный вопрос, рассматривае...мый в предлагаемом техническом руководстве, заключается в том, как
обеспечить возможности быстрого развертывания сил и средств для оказания неотложной помощи и
интенсивного лечения больных COVID-19 при сохранении основных видов больничных услуг.
more
Working Document Nov. 2020
The COVAX Supply and Logistics workstream lead by UNICEF, Gavi and WHO have released a working copy of the COVID-19 Vaccination, Country Readiness & Delivery: Supply and Logistics Guidance. Countries might find this Guide useful when developing and strengthening their sup...ply chain strategies to receive, store, distribute and manage the COVID-19 vaccines and their ancillary products, in line with their national deployment and vaccination plan (NDVP). The document also provides links to the different tools and resources to aid countries in performing assessment, planning and capacity-building activities.
more
Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status,... which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry
more
“Guide to facilitate the implementation of the WHO/UNICEF “Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines” for Africa
14 March 2022. Ukraine emergency response
WHO appreciates offers of contributions of supply support in solidarity with the affected population of the current conflict in Ukraine.
Please note that supply into and within Ukraine is seriously constrained by continuously shifting conflict zones, d...amage to infrastructure and potential shortages of power and fuel. The WHO priority is to supply critically needed items in a manner that is safe, secure, and responsive to the environment in which we are operating in. Access constraints require that logistics planning and capacity are paramount if supplies are to move smoothly to destinations where they are needed.
more
22 April 2022, This document provides updated interim recommendations on the use of masks by health workers providing care to patients with suspected or confirmed COVID-19. This update is prompted by new evidence around mask use and COVID-19 transmission, as well as the emergence of variants of conc...ern including Omicron. Masks continue to be a critical tool to prevent the spread of COVID-19. These interim guidelines supersede the recommendations provided in the WHO recommendations on mask use by health workers, in light of the Omicron variant of concern published on 22 December 2022.
WHO continually evaluates the emerging evidence and will review these interim recommendations within two months and issue new guidance as needed.
more
The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological
situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171
countries across all six WHO Regions and was rapidly re...placing Delta worldwide – was considered Omicron has a substantial growth advantage, higher secondary attack rates and a higher observed reproduction number than Delta.
There is now significant evidence that immune evasion contributes to the rapid spread of Omicron. Other factors may be a shorter
serial interval (by about 0.8 to 1.2 days compared to Delta) and potential increased intrinsic transmission fitness . There is
growing evidence that with Omicron, there is lower vaccine effectiveness (VE) against infection and symptomatic disease soon after vaccination compared to Delta. There is also evidence of accelerated waning of VE over time of the primary series against infection and symptomatic disease for the studied vaccines. Further studies are required to better understand the drivers of transmission and declining incidence in various settings. These factors include the intrinsic transmission fitness properties of the virus, degree of immune evasion, vaccination coverage and level of vaccine-derived and post-infection immunity, levels of social mixing and degree of application of public health and social measures (PHSM).
more